Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Nurix Therapeutics (NRIX) Operating Expenses (2019 - 2025)

Historic Operating Expenses for Nurix Therapeutics (NRIX) over the last 7 years, with Q4 2025 value amounting to $96.7 million.

  • Nurix Therapeutics' Operating Expenses rose 2403.23% to $96.7 million in Q4 2025 from the same period last year, while for Nov 2025 it was $369.6 million, marking a year-over-year increase of 3814.62%. This contributed to the annual value of $369.6 million for FY2025, which is 3814.62% up from last year.
  • Nurix Therapeutics' Operating Expenses amounted to $96.7 million in Q4 2025, which was up 2403.23% from $99.3 million recorded in Q3 2025.
  • In the past 5 years, Nurix Therapeutics' Operating Expenses ranged from a high of $99.3 million in Q3 2025 and a low of $29.5 million during Q1 2021
  • Moreover, its 5-year median value for Operating Expenses was $58.0 million (2022), whereas its average is $62.0 million.
  • In the last 5 years, Nurix Therapeutics' Operating Expenses soared by 9242.48% in 2021 and then skyrocketed by 51.45% in 2023.
  • Over the past 5 years, Nurix Therapeutics' Operating Expenses (Quarter) stood at $45.3 million in 2021, then rose by 22.32% to $55.5 million in 2022, then rose by 9.05% to $60.5 million in 2023, then increased by 28.84% to $77.9 million in 2024, then increased by 24.03% to $96.7 million in 2025.
  • Its Operating Expenses was $96.7 million in Q4 2025, compared to $99.3 million in Q3 2025 and $92.4 million in Q2 2025.